5
Boston Commerce
BOSTONBIOSYSTEMSLTD NSE
Boston Commerce
Healthcare ServicesNSE: BOSTONBIOSYSTEMSLTD BSE: 531458 Healthcare Service Provider
Key Fundamentals
MicrocapHealthcare Service ProviderHealthcare ServicesMarket Cap
₹3.10 Cr
Volatility
Moderate
P/E Ratio
-5.4
EBITDA
₹0.01 Cr
Return on Equity
-9.27%
Debt to Equity
0.18
Book Value
₹7.6
52W High
₹10.95
52W Low
₹4.01
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Stock is trading at 0.63 times its book value
Weaknesses
4- Company has low interest coverage ratio.
- Promoter holding is low: 2.14%
- Company has a low return on equity of -6.94% over last 3 years.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
140%
Net Income Growth
16% lower than
3Y
Cash Flow Change
-4.59% level than
3Y
ROE
325% higher than
3Y
ROCE
143%
EBITDA Margin (Avg.)
-101%
Quarterly Results
| Particulars | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.19 | 0.18 | 0.24 | 0.06 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0.14 | 0 | 0.01 | 0.05 | 0.68 | 0.1 | 0.14 | 0.04 | 0.08 |
| Operating Profit | 0 | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.08 | 0.1 | 0.02 | -0.08 |
| OPM % | — | — | — | — | — | — | — | — | -257.89% | 44.44% | 41.67% | 33.33% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.05 | 0.03 | 0.59 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.05 | 0.05 | -0.01 | -0.67 |
| Tax % | — | — | — | — | 0% | — | 0% | 0% | 0% | 20% | 20% | 0% | -4.48% |
| Net Profit | 0 | 0 | 0 | 0 | -0.14 | 0 | -0.01 | -0.05 | -0.49 | 0.04 | 0.04 | -0.01 | -0.65 |
| EPS in Rs | 0 | 0 | 0 | 0 | -0.2 | 0 | -0.01 | -0.07 | -0.7 | 0.06 | 0.06 | -0.01 | -0.93 |
Profit & Loss
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.12 | 0.15 | 0.05 | 0.06 | 1.5 | 0.53 | 0.7 | 0 | 0 | 0 | 0.19 | 0.48 |
| Expenses | 0.27 | 0.16 | 0.05 | 0.06 | 1.5 | 0.53 | 0.7 | 0 | 0 | 0.14 | 0.74 | 0.47 |
| Operating Profit | -0.15 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | 0.01 |
| OPM % | -125% | -6.67% | 0% | 0% | 0% | 0% | 0% | — | — | — | -289.47% | 2.08% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.59 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.15 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | -0.58 |
| Tax % | 0% | 0% | — | — | — | — | — | — | — | 0% | 0% | 0% |
| Net Profit | -0.15 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.14 | -0.55 | -0.58 |
| EPS in Rs | -0.21 | -0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.2 | -0.79 | -0.83 |
| Div. Payout % | 0% | 0% | — | — | — | — | — | — | — | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.41 | -0.41 | -0.55 | -1.1 | -1.68 |
| Borrowings | 0.14 | 0.12 | 0.12 | 0.12 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 5.44 | 0.96 |
| Other Liabilities | 0 | -0.01 | -0.01 | -0.01 | 1.46 | 1.9 | 2.6 | 3.11 | 3.11 | 3.25 | 3.57 | 1.09 |
| Total Liabilities | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
| Total Assets | 6.74 | 6.71 | 6.71 | 6.71 | 8.93 | 9.37 | 10.07 | 10.57 | 10.57 | 10.57 | 14.91 | 7.37 |
Cash Flow
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1 | 0 | 0 | 0.97 | -0.03 | -0.02 | 0.13 | 0 | 0 | 0 | -4.59 | 5.12 |
| Investing | 0 | 0 | 0 | -0.91 | 0 | 0 | -0.08 | 0 | 0 | 0 | 0 | 0 |
| Financing | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.58 | -5.08 |
| Net Cash Flow | 0 | 0 | 0 | 0.06 | -0.03 | -0.02 | 0.05 | 0 | 0 | 0 | -0.01 | 0.04 |
| Free Cash Flow | 1 | 0 | 0 | 0.97 | -0.03 | -0.02 | 0.13 | 0 | 0 | 0 | -4.59 | 5.12 |
| CFO/OP | -667 | 0 | — | — | — | — | — | — | — | 0 | 835 | 51,200 |
Ratios
| Particulars | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 363 | 1,343 | 1,309 | — | — | — | 5,533 | 0 |
| Inventory Days | 0 | 0 | — | — | 0 | 0 | 11.59 | — | — | — | — | — |
| Days Payable | — | — | — | — | — | — | 1,489 | — | — | — | — | — |
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 363 | 1,343 | -169 | — | — | — | 5,533 | 0 |
| Working Capital Days | -426 | -292 | -876 | 4,745 | 226 | 661 | 454 | — | — | — | 10,585 | 836 |
| ROCE % | -2.05% | -0.15% | 0% | 0% | 0% | 0% | 0% | — | 0% | -1.89% | -5.89% | 0.11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Boston Commerce insights
60 extracted metrics + investor summaries across FY00–FY26.
Documents
1
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th September, 2026
11 Sep - Board approved FY26 audited results, AGM on Sept 30, 2026, and auditor appointments. 11 Sep - Board approved FY26 audited results, AGM on Sept 30, 2026, and auditor appointments.
2
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
11 Sep - Board approved FY26 audited results, AGM on September 30, 2026, and auditor appointments. 11 Sep - Board approved FY26 audited results, AGM on September 30, 2026, and auditor appointments.
3
Reg. 34 (1) Annual Report.
11 Sep - FY26 annual report and AGM notice for 30 Sep 2026; MD/CFO resigned, Archana Pandya appointed WTD/CFO. 11 Sep - FY26 annual report and AGM notice for 30 Sep 2026; MD/CFO resigned, Archana Pandya appointed WTD/CFO.
4
Notice For Closure Of Transfer Books For 31St Annual General Meeting Of The Company.
11 Sep - Book closure from Sept 24-30, 2026 for 31st AGM on Sept 30, with e-voting Sept 27-29. 11 Sep - Book closure from Sept 24-30, 2026 for 31st AGM on Sept 30, with e-voting Sept 27-29.
5
Letter To Shareholders Pursuant To Regulation 36(1)(B) Of The SEBI Listing Regulations
11 Sep - Annual report FY2025-26 shared; 31st AGM on September 30, 2026 via VC/OAVM. 11 Sep - Annual report FY2025-26 shared; 31st AGM on September 30, 2026 via VC/OAVM.
1
Intimation Regarding Cancellation Of Board Meeting Scheduled To Be Held On Friday 21St August 2026 21 Aug 2026
General_Announcements
Frequently Asked Questions about Boston Commerce
What does Boston Commerce Limited do?
Incorporated in 1995, Boston Bio Systems
Ltd is in the business of trading in goods
e.g. Medical equipment, testing kits,
instruments etc.[1]
Where is Boston Commerce Limited (531458) listed?
Boston Commerce Limited trades as BOSTONBIOSYSTEMSLTD on the NSE and under code 531458 on the BSE.
Which sector does Boston Commerce Limited belong to?
Boston Commerce Limited is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Boston Commerce Limited?
Boston Commerce Limited has a market capitalisation of ₹3.1 Cr, which places it in the Small Cap band.
What is the PE ratio of Boston Commerce Limited?
Boston Commerce Limited trades at a PE ratio of -5.40, against a book value of ₹7.6 per share.
What is the 52-week high and low of Boston Commerce Limited?
Over the last 52 weeks Boston Commerce Limited has traded between ₹4.01 and ₹10.95.
What is the Return on Equity (ROE) of Boston Commerce Limited?
Boston Commerce Limited reported a return on equity of -9.27%. Its debt-to-equity ratio is 0.18.
Company Information
Incorporated in 1995, Boston Bio Systems Ltd is in the business of trading in goods e.g. Medical equipment, testing kits, instruments etc.[1]
Website bostonbiosystemltd.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531458.md for Boston Commerce Limited: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.